The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
New treatments for cocaine dependence: a focused review
Open accessAbstract
Cocaine, already a significant drug problem in North and South America, has become a more prominent part of the European drug scene. Cocaine dependence has major somatic, psychological, psychiatric, socio-economic, and legal implications. No specific effective pharmacological treatment exists for cocaine dependence. Recent advances in neurobiology have identified various neuronal mechanisms implicated in cocaine addiction and suggested several promising pharmacological approaches. Data were obtained from Medline, EMBASE, and PsycINFO searches of English-language articles published between 1985 and June 2007 using the key words: cocaine, addiction, cocaine dependence, clinical trials, pharmacotherapy(ies) singly and in combination. Large well-controlled studies with appropriate statistical methods were preferred. Pharmacological agents such as GABA agents (topiramate, tiagabine, baclofen and vigabatrin) and agonist replacement agents (modafinil, disulfiram, methylphenidate) seem to be the most promising in treatment of cocaine dependence. The results from trials of first- and second-generation neuroleptics are largely negative. Aripiprazole, a partial dopaminergic agonist that may modulate the serotonergic system, shows some promise. Preliminary results of human studies with anti-cocaine vaccine, N-acetylcysteine, and ondansetron, are promising, as are several compounds in preclinical development. While no medication has received regulatory approval for the treatment of cocaine dependence, several medications marketed for other indications have shown efficacy in clinical trials. An anti-cocaine vaccine and several compounds in preclinical development have also shown promise. Findings from early clinical trials must be confirmed in larger, less selective patient populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Addiction, Dysregulation of Reward, and Allostasis
Koob, G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00195-0 · Cited by 2,953
Goldstein, R. Z., & Volkow, N. D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.10.1642 · Cited by 2,667
Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction
Volkow, N. D., Wang, G.-J., Telang, F., Fowler, J. S., Logan, J., Childress, A.-R., Jayne, M., Ma, Y., & Wong, C. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1544-06.2006 · Cited by 1,164
Wise, R. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00965-0 · Cited by 881
Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission
Kalivas, P. W., Volkow, N., & Seamans, J. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.005 · Cited by 657
Sinha, R., Garcia, M., Paliwal, P., Kreek, M. J., & Rounsaville, B. J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.324 · Cited by 528
Camí, J., & Farré, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023160 · Cited by 477
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391 · cited 10×
“The first randomized, double-blind clinical trial involved 40 cocaine-dependent outpatientswho received topiramate (up to 200 mg/d) or placebo for 13 wk, in conjunction with twice weekly CBT (Kampman et al., 2004).”
MethodInfluentialThe Status of Disulfiram: A Half of a Century Later
Suh, J. J., Pettinati, H. M., Kampman, K. M., & O'Brien, C. P. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000222512.25649.08 · Cited by 382 · cited 2×
“Disulfiram: a dopamine metabolism inhibitor Disulfiram has been used for more than half a century in the treatment of alcoholism (Suh et al., 2006).”
BackgroundDextroamphetamine for Cocaine-Dependence Treatment: A Double-Blind Randomized Clinical Trial
Grabowski, J., Rhoades, H., Schmitz, J., Stotts, A., Daruzska, L. A., Creson, D., & Moeller, F. G. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00010 · Cited by 243 · cited 1×
“Three double-blind, placebo-controlled studies using d-amphetamine (15–60 mg/d sustained-release formulation) in cocaine-dependent or in cocaine- and heroin-dependent patients showed decreased cocaine use at the higher doses (30–60 mg/d) (Grabowski et al., 2001, 2004a; Shearer et al., 2003).”
Background
Cited by
Metabotropic glutamate receptors: From the workbench to the bedside
Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp, D. D., Wroblewski, J. T., & Pin, J. P. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.022 · Cited by 653
Emerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381
Treatment of substance abusing patients with comorbid psychiatric disorders
Kelly, T. M., Daley, D. C., & Douaihy, A. B. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2011.09.010 · Cited by 284
Terraneo, A., Leggio, L., Saladini, M., Ermani, M., Bonci, A., & Gallimberti, L. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.11.011 · Cited by 281
Dakwar, E., Levin, F., Foltin, R. W., Nunes, E. V., & Hart, C. L. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.009 · Cited by 143
Metadata
- Authors
- Karila, L., Gorelick, D., Weinstein, A., Noble, F., Benyamina, A., Coscas, S., Blecha, L., Lowenstein, W., Martinot, J. L., Reynaud, M., & Lépine, J. P.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-10
- Volume
- 11
- Issue
- 03
- Pages
- 425-38
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2161817834
- Cited by
- 178
- References
- 14
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New treatments for cocaine dependence: a focused review. https://app.cochat.ai/papers/10.1017/s1461145707008097
- The paper
- Karila, L., Gorelick, D., Weinstein, A., Noble, F., Benyamina, A., Coscas, S., Blecha, L., Lowenstein, W., Martinot, J. L., Reynaud, M., & Lépine, J. P. (2008). New treatments for cocaine dependence: a focused review. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145707008097
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.